Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jill S Lindberg

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 28, 2004
Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4Jack W Coburn, Hla M Maung, Logan Elangovan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 28, 2002
Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patientsAllen R Nissenson, Suzanne K Swan, Jill S Lindberg, et al.
Kidney International|December 11, 2002
The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidismJill S Lindberg, Sharon M Moe, William G Goodman, et al.
Journal of the American Society of Nephrology : JASN|February 4, 2005
Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter studyJill S Lindberg, Bruce Culleton, Gordon Wong, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 28, 2004
Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4Jack W Coburn, Hla M Maung, Logan Elangovan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 28, 2002
Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patientsAllen R Nissenson, Suzanne K Swan, Jill S Lindberg, et al.
Kidney International|December 11, 2002
The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidismJill S Lindberg, Sharon M Moe, William G Goodman, et al.
Journal of the American Society of Nephrology : JASN|February 4, 2005
Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter studyJill S Lindberg, Bruce Culleton, Gordon Wong, et al.
Pageof 2